Patents by Inventor Igor Theurl

Igor Theurl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS, REGIMENS, COMBINATIONS & ANTAGONISTS
    Publication number: 20230233675
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Application
    Filed: August 11, 2022
    Publication date: July 27, 2023
    Applicant: Kymab Limited
    Inventors: Volker GERMASCHEWSKI, Igor THEURL, Martin YATEMAN, Jasper CLUBE, Steve ARKINSTALL
  • Methods, regimens, combinations and antagonists
    Patent number: 11648308
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 16, 2023
    Assignee: Kymab Limited
    Inventors: Volker Germaschewski, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
  • METHODS OF USING MOMELOTINIB TO TREAT JOINT INFLAMMATION
    Publication number: 20230078511
    Abstract: The disclosure provides methods of treating joint inflammation, including rheumatoid arthritis, in a subject using mo-melotinib (MMB).
    Type: Application
    Filed: January 28, 2021
    Publication date: March 16, 2023
    Inventors: Igor THEURL, Ryan James HANSEN, Christian Andrew HASSIG
  • TREATMENT FOR PHYSIOLOGICAL IRON OVERLOAD
    Publication number: 20230025129
    Abstract: Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 26, 2023
    Inventors: Matthew WAKE, Volker GERMASCHEWSKI, Igor THEURL, Jonathan Leslie PAPWORTH, Delphine MEYNARD
  • ANTAGONISTS
    Publication number: 20220073598
    Abstract: The invention relates to Bone Morphogenetic Protein 6 (BMP6) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
    Type: Application
    Filed: August 15, 2019
    Publication date: March 10, 2022
    Inventors: Volker GERMASCHEWSKI, Igor THEURL, Joana de Abreu CARVALHO, Morgane Marie LECOINTRE, Jonathan Leslie PAPWORTH, Luke Thomas BAYLISS, Verena PETZER
  • ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
    Publication number: 20210214456
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases. The invention also relates to a transferrin receptor 2 inhibitor for use in the treatment of bone diseases, iron metabolism disorders or hematopoietic disorders.
    Type: Application
    Filed: June 11, 2019
    Publication date: July 15, 2021
    Inventors: Martina RAUNER, Lorenz HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT, Igor THEURL, Volker GERMASCHEWSKI
  • Treatment of ACVR1-mediated diseases
    Patent number: 10245268
    Abstract: Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: April 2, 2019
    Assignee: Sierra Oncology, Inc.
    Inventors: Brian Koh, Igor Theurl, Matthew Robert Warr, James Andrew Whitney
  • TREATMENT OF ACVR1-MEDIATED DISEASES
    Publication number: 20180042933
    Abstract: Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.
    Type: Application
    Filed: August 8, 2017
    Publication date: February 15, 2018
    Inventors: Brian Koh, Igor Theurl, Matthew Robert Warr, James Andrew Whitney
  • Methods, Regimens, Combinations & Antagonists
    Publication number: 20170319689
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 9, 2017
    Applicant: Kymab Limited
    Inventors: Volker GERMASCHEWSKI, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall